BP1001-A

antisense oligonucleotide targeting Bcl-2 · Bio-Path Holdings, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BP1001-A, covering 2025-03-07 to 2025-03-07. Get the full timeline:

Most recent: Clinical Trial Update: BP1001-A in Patients With Advanced or Recurrent Solid Tumors [Phase 1]